drugset / Trial / NCT07471217

[¹⁴C] Hydronidone Mass Balance Study

NCT07471217

Phase 1 Not yet recruiting 8 enrolled Beijing Continent Pharmaceutical Co, Ltd.
NaSingle-groupOpen-labelTreatment

Summary

According to the "Technical Guidelines for Radioactive Labeled Human Mass Balance Studies" issued by the NMPA, human mass balance studies are an important component of clinical pharmacology research for innovative drugs, and it is recommended that mass balance studies be conducted for all new molecular entities. Therefore, to further clarify the absorption, metabolism, and excretion characteristics of Hydronidone in the human body, a \[¹⁴C\] Hydronidone mass balance study is planned in Chinese healthy adult male participants. This study aims to reveal the pharmacokinetic characteristics of Hydronidone and provide a reference for the rational use of the drug.

Timeline

Start
2026-04-30
Primary completion
2026-07-30
Completion
2026-07-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Hydronidone Small molecule 90 mg Oral